KR20240154641A - Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 - Google Patents

Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 Download PDF

Info

Publication number
KR20240154641A
KR20240154641A KR1020247032358A KR20247032358A KR20240154641A KR 20240154641 A KR20240154641 A KR 20240154641A KR 1020247032358 A KR1020247032358 A KR 1020247032358A KR 20247032358 A KR20247032358 A KR 20247032358A KR 20240154641 A KR20240154641 A KR 20240154641A
Authority
KR
South Korea
Prior art keywords
domain
seq
fab
antibody
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032358A
Other languages
English (en)
Korean (ko)
Inventor
유진 주코브스키
피에르-엠마뉘엘 제라르
크리스뗄 라르부르
라비아 에밀리아
티에리 샤르데
앙드레 펠레그랭
Original Assignee
바이오뮤넥스 파마슈티컬스
유니베르시테 드 몽펠리에
앵스띠뛰 레지오날 뒤 깡세르 드 몽뻴리에 (아이씨엠)
앵스띠뛰 레지오날 뒤 깡세르 드 몽–y리에 (아이씨엠)
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오뮤넥스 파마슈티컬스, 유니베르시테 드 몽펠리에, 앵스띠뛰 레지오날 뒤 깡세르 드 몽뻴리에 (아이씨엠), 앵스띠뛰 레지오날 뒤 깡세르 드 몽–y리에 (아이씨엠), 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) filed Critical 바이오뮤넥스 파마슈티컬스
Publication of KR20240154641A publication Critical patent/KR20240154641A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247032358A 2022-03-02 2023-03-01 Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 Pending KR20240154641A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305242.4 2022-03-02
EP22305242 2022-03-02
PCT/EP2023/055243 WO2023166098A1 (en) 2022-03-02 2023-03-01 Bispecific antibodies binding to her-3 and to either her-2 or egfr

Publications (1)

Publication Number Publication Date
KR20240154641A true KR20240154641A (ko) 2024-10-25

Family

ID=80930221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032358A Pending KR20240154641A (ko) 2022-03-02 2023-03-01 Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체

Country Status (9)

Country Link
US (1) US20250282892A1 (enExample)
EP (1) EP4486774A1 (enExample)
JP (1) JP2025510539A (enExample)
KR (1) KR20240154641A (enExample)
CN (1) CN119451982A (enExample)
AU (1) AU2023228330A1 (enExample)
CA (1) CA3244947A1 (enExample)
TW (1) TW202342538A (enExample)
WO (1) WO2023166098A1 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
BR112013003257A2 (pt) 2010-08-10 2016-06-14 Glycotope Gmbh anticorpos egfr humanizados.
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP5786839B2 (ja) 2012-12-05 2015-09-30 株式会社デンソー エポキシ樹脂組成物および接着構造体の製造方法
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
WO2020136566A1 (en) 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains

Also Published As

Publication number Publication date
TW202342538A (zh) 2023-11-01
JP2025510539A (ja) 2025-04-15
EP4486774A1 (en) 2025-01-08
AU2023228330A1 (en) 2024-09-19
CA3244947A1 (en) 2023-09-07
US20250282892A1 (en) 2025-09-11
CN119451982A (zh) 2025-02-14
WO2023166098A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7589314B2 (ja) 抗ｐｄ－１／抗ｖｅｇｆａ二官能性抗体、その医薬組成物およびその使用
JP7736772B2 (ja) ＥＧＦＲ及びｃＭＥＴに結合する抗体
KR102360742B1 (ko) Egfr 및 her2 를 표적하는 이특이적 항체
KR102469286B1 (ko) 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도
KR102361412B1 (ko) Cd38 및 pd-l1에 대한 결합 분자
TW201302790A (zh) 單特異性及雙特異性抗ｉｇｆ－１ｒ及抗ｅｒｂｂ３抗體
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
US20250382386A1 (en) Anti-alk-1 antibody and use thereof
US20180017572A1 (en) Assay and method for determining cdc eliciting antibodies
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
HK40073118A (en) Binding molecules to cd38 and pd-l1
HK40073118B (en) Binding molecules to cd38 and pd-l1
HK40002344B (en) Binding molecules to cd38 and pd-l1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000